Legato Capital Management LLC Purchases New Shares in Roivant Sciences Ltd. $ROIV

Legato Capital Management LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 32,205 shares of the company’s stock, valued at approximately $487,000.

A number of other hedge funds also recently bought and sold shares of ROIV. Jones Financial Companies Lllp boosted its holdings in shares of Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after buying an additional 1,148 shares during the period. Bessemer Group Inc. lifted its position in shares of Roivant Sciences by 41.5% in the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares in the last quarter. CWM LLC boosted its stake in Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock worth $34,000 after purchasing an additional 920 shares during the period. Osaic Holdings Inc. grew its position in Roivant Sciences by 204.2% during the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock worth $65,000 after purchasing an additional 3,882 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd raised its stake in Roivant Sciences by 75.8% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company’s stock valued at $67,000 after purchasing an additional 1,900 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ROIV. Citigroup raised their target price on Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, February 10th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. TD Cowen reaffirmed a “buy” rating on shares of Roivant Sciences in a research report on Wednesday. HC Wainwright increased their target price on shares of Roivant Sciences from $33.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Tuesday. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Roivant Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $28.81.

Roivant Sciences News Roundup

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant (via subsidiary Genevant) and Arbutus announced a $2.25 billion global settlement with Moderna that includes a $950M upfront payment and up to $1.3B contingent on a favorable appeal — a major cash and litigation-risk removal for Roivant’s LNP business. Read More.
• Positive Sentiment: The board approved an expanded $1 billion share repurchase program (inclusive of a prior $500M authorization), which supports buyback-driven EPS/reduced share float dynamics and likely contributed to the rally. Read More.
• Positive Sentiment: Priovant (a Roivant affiliate) received FDA acceptance and Priority Review for brepocitinib in dermatomyositis with a PDUFA date in Q3 2026 — approval would create a first-in-class targeted therapy and potential commercial upside. Read More.
• Positive Sentiment: HC Wainwright raised its price target to $34 and maintained a Buy rating, providing analyst support and signaling ~15% upside from current levels. Read More.
• Neutral Sentiment: The $1.3B additional payment is contingent on a favorable resolution of Moderna’s Section 1498 appeal — meaningful upside but dependent on litigation outcome and timing, introducing uncertainty to the total cash Roivant ultimately receives. Read More.
• Negative Sentiment: Pfizer/BioNTech litigation remains ongoing in the U.S.; while the Moderna settlement materially de-risks one front, continued legal exposure and appeals across the sector leave some patent and revenue uncertainty. Read More.

Insider Buying and Selling at Roivant Sciences

In related news, CEO Matthew Gline sold 1,740,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $21.68, for a total value of $37,723,200.00. Following the transaction, the chief executive officer directly owned 17,290,820 shares of the company’s stock, valued at approximately $374,864,977.60. This trade represents a 9.14% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel Allen Gold sold 917,282 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $23.04, for a total value of $21,134,177.28. Following the completion of the sale, the director owned 17,130,445 shares of the company’s stock, valued at approximately $394,685,452.80. This trade represents a 5.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 13,318,014 shares of company stock worth $315,727,023 in the last 90 days. Company insiders own 10.80% of the company’s stock.

Roivant Sciences Stock Up 6.0%

Shares of ROIV opened at $29.52 on Thursday. The firm has a market cap of $21.13 billion, a price-to-earnings ratio of -25.23 and a beta of 1.17. The company’s fifty day moving average is $24.28 and its 200-day moving average is $19.85. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $29.83.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.